

UNITED STATES ENVIRONMENTAL PROTECTION AGENCY  
REGION 2

IN THE MATTER OF:	)	Docket No RCRA-02-2022-7205
	)	
	)	
Edenbridge Pharmaceuticals, LLC	)	EXPEDITED SETTLEMENT AGREEMENT
	)	AND
	)	FINAL ORDER
Respondent	)	
_____	)	

**EXPEDITED SETTLEMENT AGREEMENT**

1. The United States Environmental Protection Agency (“EPA”) is authorized to enter into this Expedited Settlement Agreement (hereafter referred to as “Agreement”) pursuant to Section 3008 of the Resource Conservation and Recovery Act, as amended (“RCRA”) and 40 C.F.R. § 22.13(b).
2. EPA has notified the State of New Jersey of this action.
3. Edenbridge Pharmaceuticals, LLC (hereafter “Respondent”) is the owner or operator of the facility located at 169 Lackawanna Avenue, Suite 110, Parsippany, New Jersey 07054 (“Facility”). The EPA conducted a review of e-manifest data of hazardous waste shipments from this Facility and had discussions with Respondent regarding its findings.
4. EPA has determined that Respondent failed to have an EPA identification number prior to transporting or offering for transport hazardous waste from its Facility. Specifically, during the years 2018-2020 Respondent shipped hazardous waste from its Facility using hazardous waste manifest(s) without having received an EPA identification number from the New Jersey Department of Environmental Protection in violation of 40 C.F.R. § 262.12 (1998), as incorporated by reference by N.J.A.C. 7:26G-6.1(a).
5. The EPA and Respondent agree that settlement of this matter for a civil penalty of **one thousand two hundred and fifty dollars (\$1,250.00)** is in the public interest.
6. In signing this Agreement, Respondent: (1) admits that it is subject to RCRA and New Jersey State’s authorized hazardous waste program; (2) admits that EPA has jurisdiction over Respondent and Respondent’s conduct as described herein; (3) neither admits nor denies the allegations contained herein; (4) consents to the assessment of this penalty; (5) waives the opportunity for a hearing pursuant to Section 3008(b) of RCRA to contest any issue of fact or law set forth herein; (6) waives its right to appeal the Final Order accompanying this Agreement; and (7) consents to electronic service of the final Agreement.

7. By its signature below Respondent certifies that no portion of the civil penalty or interest paid by Respondent pursuant to the requirements of this Agreement will be claimed by Respondent as a deduction for federal income tax purposes.
8. By its signature below Respondent certifies, subject to civil and criminal penalties for making a false submission to the United States Government, that: (1) it has now complied with the regulatory requirement cited in Paragraph 4 above, and (2) Respondent has submitted proof of payment of the civil penalty in connection with this Agreement.
9. The undersigned representative of Respondent certifies that he or she is fully authorized to enter the terms and conditions of this Agreement and to execute and legally bind Respondent to it.
10. Full payment of the penalty described in Paragraph 5 above shall only resolve Respondent's liability under RCRA for federal civil penalties for the violation and facts described in Paragraph 4. Full payment of this penalty shall not in any case affect the right of EPA or the United States to pursue appropriate injunctive relief or other equitable relief or criminal sanctions for any violation of law.
11. Each party shall bear its own costs and fees, if any.
12. This Agreement is binding on the parties signing below, and in accordance with 40 C.F.R. § 22.31(b), shall be effective upon the filing of the Final Order with the Regional Hearing Clerk for EPA, Region 2.

IT IS SO AGREED,

**RESPONDENT:**

Edenbridge Pharmaceuticals, LLC

Name of individual signing (type or print): \_\_\_\_\_

\_\_\_\_\_  
Name (Signature)

Date: \_\_\_\_\_

\_\_\_\_\_  
Title (print)

**In the Matter of Edenbridge Pharmaceuticals, LLC  
Docket Number RCRA-02-2022-7205**

**COMPLAINANT:**

\_\_\_\_\_  
***for* Dore F. LaPosta, Director  
Enforcement and Compliance Assurance Division**

Date: \_\_\_\_\_

**In the Matter of Edenbridge Pharmaceuticals, LLC  
Docket Number RCRA-02-2022-7205**

FINAL ORDER

The Regional Judicial Officer of the U.S. Environmental Protection Agency, Region 2, ratifies the foregoing Expedited Settlement Agreement. This Agreement, entered into by the parties to this matter, is hereby approved, incorporated herein, and issued as an Order pursuant to Section 3008 of the Act and 40 C.F.R. § 22.18(b)(3). The Effective Date of this Order shall be the date of its filing with the Regional Hearing Clerk, U.S. Environmental Protection Agency, Region 2, New York, New York. 40 C.F.R. § 22.31 (b).

IT IS SO ORDERED:

\_\_\_\_\_  
**Helen Ferrara, Regional Judicial Officer  
U.S. Environmental Protection Agency – Region 2  
290 Broadway  
New York, New York 10007-1866**

Date: \_\_\_\_\_